ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Eyeing Novartis deal, Akcea trumpets lipoprotein drug data
December 11, 2018Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal...... -
US nod for Akcea/Ionis’ Tegsedi
October 11, 2018Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid... -
PTC Therapeutics to commercialise Akcea’s two rare disease drugs
August 06, 2018Ionis Pharmaceuticals affiliate Akcea Therapeutics has signed an agreement with biopharmaceutical company PTC Therapeutics for the commercialisation of its rare disease drugs Tegsedi (inotersen) and Waylivra (volanesorsen) in Latin America. -
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal
March 16, 2018In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases -
Akcea’s rare lipid disorder drug wins PIM status
October 11, 2017Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome , a rare genetic lipid disorder.
Pharma Sources Insight January 2025
